07:00 , Jun 9, 2008 |  BioCentury  |  Product Development

No regrets

Although it is now chasing other compounds in the clinic, Seattle Genetics Inc. has no regrets over its decision three years ago to shelve its SGN-15 first-generation antibody-drug conjugate in favor of the second-generation compound,...
08:00 , Nov 12, 2007 |  BC Week In Review  |  Company News

Crucell, DSM Biologics N.V., Recepta Biopharma S.A. deal

Crucell N.V. (Euronext:CRXL; CRXL), Leiden, the Netherlands   DSM Biologics N.V., Heerlen, the Netherlands   Recepta Biopharma S.A., Sao Paulo, Brazil   Business: Supply/Service, Antibodies   CRXL and its manufacturing partner, DSM, granted Recepta a non-exclusive license to...
07:00 , Jul 17, 2006 |  BioCentury  |  Strategy

Wyeth's biologics pipeline

Wyeth's biologics pipeline Product (Partner) Target/mechanism Indication Status BeneFIX reformulation (A) Factor IX Hemophilia B Ph III ReFacto next generation (A) Factor VIII Hemophilia A Ph III AAB-001 bapineuzumab (Elan) Anti-beta amyloid MAb Alzheimer's disease...
08:00 , Feb 13, 2006 |  BC Week In Review  |  Company News

Aphton, Celltrion deal

APHT's Igeneon subsidiary (Vienna, Austria) and Celltrion signed a letter of intent to amend a 2005 deal in which Igeneon granted Celltrion commercialization rights to IGN311 in certain Asian countries, including Japan (see BioCentury, Aug....
07:00 , Aug 1, 2005 |  BC Week In Review  |  Company News

Aphton, Celltrion deal

APHT's Igeneon subsidiary (Vienna, Austria) granted Celltrion commercialization rights to IGN311 in certain Asian countries, including Japan. The monoclonal antibody targeting the Lewis Y antigen is in Phase I trials to treat epithelial cancer....
07:00 , Jul 25, 2005 |  BC Week In Review  |  Clinical News

IGN311: Phase I/II started

APHT began an open-label, European, Phase I/II trial in up to 24 patients. Aphton Corp. (APHT), Miami, Fla.   Product: IGN311   Business: Cancer   Molecular target: Lewis Y antigen   Description: Human monoclonal antibody against Lewis Y...
07:00 , Jul 18, 2005 |  BC Week In Review  |  Clinical News

IGN311: Phase I data

In an open-label, dose-escalation, German Phase I trial in 12 epithelial cancer patients, IGN311 was well tolerated with a serum half-life of >20 days. Patients received 50, 100 or 200 mg IV IGN311 on the...
07:00 , Jul 11, 2005 |  BC Week In Review  |  Clinical News

SGN-15: Development discontinued

In an open-label Phase II trial in NSCLC patients assessing the optimal dose schedule showed that administration of SGN-15, 3 days ahead of Taxotere, showed greater synergy and drug effect than when administered simultaneously....
07:00 , Jul 11, 2005 |  BioCentury  |  Product Development

Generation next

It is not uncommon for biotech companies to use first-generation compounds for proof of principle, with the expectation that they may shelve them once better second-generation versions are ready for the clinic. Seattle Genetics Inc....
07:00 , May 16, 2005 |  BC Week In Review  |  Company News

Aphton cancer news

APHT restructured and will reduce its headcount by 35% to about 80 from 120. The company will discontinue development of Insegia (G17DT) to treat pancreatic cancer and will withdraw its monotherapy marketing applications in Switzerland,...